{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:02:23Z","timestamp":1789596143705,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["CENTRO-01-0145-FEDER-000013"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-000013"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["UID\/Multi\/00709\/2019"],"award-info":[{"award-number":["UID\/Multi\/00709\/2019"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/Multi\/00709\/2019"],"award-info":[{"award-number":["UID\/Multi\/00709\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ejps.2019.105099","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T12:32:37Z","timestamp":1572265957000},"page":"105099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphenytoin for intranasal administration: Formulation development and in vitro characterization"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0036-4894","authenticated-orcid":false,"given":"Patr\u00edcia C.","family":"Pires","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaura","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7010-0619","authenticated-orcid":false,"given":"M\u00e1rcio","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-0714","authenticated-orcid":false,"given":"Gilberto","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-9191","authenticated-orcid":false,"given":"Adriana O.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2019.105099_bib0001","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1570-0232(02)00244-1","article-title":"Linear regression for calibration lines revisited: weighting schemes for bioanalytical methods","volume":"774","author":"Almeida","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejps.2019.105099_bib0002","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejps.2016.04.018","article-title":"Development and application of an ex vivo fosphenytoin nasal bioconversion\/permeability evaluation method","volume":"89","author":"Antunes Viegas","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105099_bib0003","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejps.2008.07.004","article-title":"Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS)","volume":"35","author":"Atef","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105099_bib0004","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.2147\/DDDT.S169621","article-title":"The retinoprotective role of phenytoin","volume":"12","author":"Bartollino","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ejps.2019.105099_bib0005","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.pharep.2014.03.009","article-title":"Antiarrhythmic drugs and epilepsy","volume":"66","author":"Borowicz","year":"2014","journal-title":"Pharmacol. Reports"},{"key":"10.1016\/j.ejps.2019.105099_bib0006","first-page":"720","article-title":"The ionic composition of nasal fluid and its function","volume":"6","author":"Burke","year":"2014","journal-title":"Health (Irvine. Calif)."},{"key":"10.1016\/j.ejps.2019.105099_bib0007","doi-asserted-by":"crossref","first-page":"709","DOI":"10.4155\/tde.14.41","article-title":"The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview","volume":"5","author":"Djupesland","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejps.2019.105099_bib0008","unstructured":"FDA, CDER, CVM, 2018. Bioanalytical method validation - guidance for industry. [WWW Document]. URL https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry (accessed 7.10.19)."},{"key":"10.1016\/j.ejps.2019.105099_bib0009","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5698\/1535-7597-16.1.48","article-title":"Evidence-based guideline: treatment of convulsive status epilepticus in children and adults - report of the Guideline Committee of the American Epilepsy Society","volume":"16","author":"Glauser","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.ejps.2019.105099_bib0010","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1152\/ajpcell.00612.2001","article-title":"In vivo microdialysis for determination of nasal liquid ion composition","volume":"282","author":"Grubb","year":"2002","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejps.2019.105099_bib0011","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.drudis.2017.09.020","article-title":"Phenytoin repositioned in wound healing: clinical experience spanning 60 years","volume":"23","author":"Hesselink","year":"2017","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.ejps.2019.105099_bib0012","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00415-017-8391-5","article-title":"Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action","volume":"264","author":"Hesselink","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejps.2019.105099_bib0013","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jconrel.2012.05.040","article-title":"Recent advances in nanocarrier-based mucosal delivery of biomolecules","volume":"161","author":"Kammona","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2019.105099_bib0014","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jconrel.2016.07.001","article-title":"A review of intranasal formulations for the treatment of seizure emergencies","volume":"237","author":"Kapoor","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2019.105099_bib0015","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.drudis.2015.10.016","article-title":"Smart materials: in situ gel-forming systems for nasal delivery","volume":"21","author":"Karavasili","year":"2016","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.ejps.2019.105099_bib0016","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3109\/10717544.2014.920431","article-title":"Nasal-nanotechnology: revolution for efficient therapeutics delivery","volume":"23","author":"Kumar","year":"2016","journal-title":"Drug. Deliv"},{"key":"10.1016\/j.ejps.2019.105099_bib0017","doi-asserted-by":"crossref","unstructured":"Marx, D., Williams, G., Birkhoff, M., 2015. Intranasal drug administration \u2014 an attractive delivery route for some drugs, in: Drug Discovery and Development - From Molecules to Medicine. pp. 299\u2013320.","DOI":"10.5772\/59468"},{"key":"10.1016\/j.ejps.2019.105099_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies","volume":"270","author":"Pires","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2019.105099_bib0019","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1586\/14737175.2015.1074523","article-title":"The safety and efficacy of fosphenytoin for the treatment of status epilepticus","volume":"15","author":"Poplawska","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejps.2019.105099_bib0020","first-page":"388","article-title":"Mathematical models of drug dissolution: a review","volume":"3","author":"Ramteke","year":"2014","journal-title":"Sch. Acad. J. Pharm."},{"key":"10.1016\/j.ejps.2019.105099_bib0021","series-title":"Handbook of pharmaceutical excipients","author":"Rowe","year":"2009"},{"key":"10.1016\/j.ejps.2019.105099_bib0026","unstructured":"<1724> Semisolid drug products, 2017. United States Pharmacopeia and National Formulary, 40th\/35th ed. United States Pharmacopeial Convention, Rockville, MD, pp. 2056\u20132067."},{"key":"10.1016\/j.ejps.2019.105099_bib0022","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejps.2014.04.019","article-title":"Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting","volume":"60","author":"Serralheiro","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2019.105099_bib0023","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","article-title":"Epilepsy treatment in adults and adolescents: expert opinion, 2016","volume":"69","author":"Shih","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ejps.2019.105099_bib0024","doi-asserted-by":"crossref","first-page":"E449","DOI":"10.1002\/lary.24811","article-title":"Effects of topical phenytoin on nasal wound healing after mechanical trauma: an experimental study","volume":"124","author":"Simsek","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejps.2019.105099_bib0025","unstructured":"U.S. Food and Drug Administration, 2019. Drugs@FDA: FDA Approved Drug Products [WWW Document]. URL https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=211321 (Accessed 7.10.19)."},{"key":"10.1016\/j.ejps.2019.105099_bib0027","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/jemt.20310","article-title":"Composition of nasal airway surface liquid in cystic fibrosis and other airway diseases determined by x-ray microanalysis","volume":"69","author":"Vanthanouvong","year":"2006","journal-title":"Microsc. Res. Tech."},{"key":"10.1016\/j.ejps.2019.105099_bib0028","first-page":"352","article-title":"Intranasal delivery of antiepileptic medications for treatment of seizures","volume":"6","author":"Wermeling","year":"2009","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.ejps.2019.105099_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2017.02.015","article-title":"Challenges in the treatment of convulsive status epilepticus","volume":"47","author":"Zaccara","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.ejps.2019.105099_bib0029","unstructured":"World Health Organization, 2017. 20th WHO model list of essential medicines. [WWW Document]. URL https:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/ (accessed 7.10.19)."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098719303720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T03:55:20Z","timestamp":1778558120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098719303720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":30,"alternative-id":["S0928098719303720"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105099","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphenytoin for intranasal administration: Formulation development and in vitro characterization","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2019.105099","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105099"}}